{"gene":"ADORA3","run_date":"2026-04-28T17:12:37","timeline":{"discoveries":[{"year":2024,"finding":"Cryo-EM structures of full-length human A3AR bound to selective agonists CF101 and CF102 in complex with heterotrimeric Gi protein were resolved at 3.3–3.2 Å resolution. The agonists occupy the orthosteric pocket with conserved interactions via their adenine moieties, while their 3-iodobenzyl groups show distinct orientations. Extracellular loop 3 plays a critical role in ligand selectivity and receptor activation. Key residues His3.37, Ser5.42, and Ser6.52 in a unique sub-pocket significantly impact receptor activation.","method":"Cryo-EM structure determination with functional mutagenesis assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 1 — atomic-resolution structure combined with functional mutagenesis validating key residues","pmids":["38627384"],"is_preprint":false},{"year":1997,"finding":"The human ADORA3 gene encodes a Gi protein-coupled receptor; the coding region is interrupted by a single intron located in the second intracellular loop, a position conserved across adenosine receptor subtypes. The gene was mapped to chromosomal locus 1p13.3 by FISH. Multiple transcription start sites were identified; the promoter lacks CAAT and TATA boxes but contains putative binding sites for multiple transcription factors.","method":"Gene cloning, sequencing, fluorescence in situ hybridisation (FISH), primer extension, 5' RACE, Northern blot","journal":"Neuroscience research","confidence":"High","confidence_rationale":"Tier 2 — direct molecular characterization of gene structure and chromosomal localization with multiple orthogonal methods","pmids":["9293494"],"is_preprint":false},{"year":1995,"finding":"The mouse A3 adenosine receptor gene (Adora3) was mapped to chromosome 3 in tight linkage with DNA marker D3Bir15, consistent with its identity as a Gi protein-coupled receptor that inhibits adenylate cyclase upon ligand binding.","method":"Interspecific backcross panel Southern hybridization and haplotype analysis","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 — direct chromosomal mapping by genetic cross; functional characterization (Gi coupling, adenylate cyclase inhibition) stated as established property","pmids":["8595892"],"is_preprint":false},{"year":2003,"finding":"A3AR activation by IB-MECA in PC-3 prostate carcinoma cells down-regulates PKAc expression, leading to increased GSK-3β protein levels, destabilization of β-catenin, and suppression of cyclin D1 and c-Myc. Concurrently, NF-κB/p65 expression is down-modulated, deregulating both Wnt and NF-κB signaling pathways to inhibit tumor cell growth.","method":"Western blot analysis of signaling proteins in vitro and in vivo (xenograft), thymidine incorporation assay","journal":"Anticancer research","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological activation combined with protein-level readouts in vitro and in vivo, but no genetic rescue or reconstitution","pmids":["12894581"],"is_preprint":false},{"year":2010,"finding":"In mouse sperm, Adora3i2 (a nested gene within Adora3) encodes a functional A3R isoform that couples through Gαi. When heterologously expressed in tsA-201 cells, Adora3i2 decreases forskolin-evoked cAMP accumulation. A3R-selective agonists (Cl-IB-MECA, IB-MECA) accelerate sperm flagellar beat frequency via pertussis-toxin-sensitive (Gαi/o) signaling; A1R, A2aR, and A2bR agonists are ineffective.","method":"Heterologous expression in tsA-201 cells with cAMP assay, pertussis toxin blockade, Adora3i1-null sperm functional assay, pharmacological profiling","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — reconstitution of isoform in heterologous cells, Gi coupling confirmed biochemically, validated with knockout sperm and pertussis toxin","pmids":["20732875"],"is_preprint":false},{"year":2015,"finding":"A3AR agonists (IB-MECA and MRS5698) reverse CCI-induced neuropathic pain via a spinal mechanism that modulates GABAergic inhibitory neurotransmission. Specifically, A3AR activation reduces CCI-related GAD65 and GAT-1 serine dephosphorylation and enhances KCC2 serine phosphorylation and activity, restoring the chloride gradient. Spinal bicuculline (GABAA antagonist) disrupts A3AR-mediated analgesia.","method":"In vivo CCI neuropathic pain models (mouse and rat), intrathecal drug administration, phosphoprotein analysis, pharmacological antagonism","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — defined pathway placement by pharmacological epistasis (bicuculline reversal) in well-characterized animal models with biochemical readouts","pmids":["25878279"],"is_preprint":false},{"year":2020,"finding":"A3AR agonists (MRS5980 and Cl-IB-MECA) inhibit N-type voltage-gated Ca2+ channels (Cav2.2) in dorsal root ganglia neurons, as demonstrated by patch-clamp recordings; this effect is blocked by the selective A3AR antagonist MRS1523 and by the selective Cav2.2 blocker PD173212, establishing Cav2.2 inhibition as a mechanism of A3AR-mediated visceral analgesia.","method":"Patch-clamp electrophysiology on isolated DRG neurons, pharmacological antagonism in vivo and in vitro","journal":"Pain","confidence":"High","confidence_rationale":"Tier 1 — direct electrophysiological measurement of ion channel inhibition by A3AR agonists, validated with selective antagonists","pmids":["32379223"],"is_preprint":false},{"year":2021,"finding":"IL-6 stimulation of T cells promotes GRK2-dependent internalization of A3AR, increasing cAMP production and reducing PKA activity, which drives Th17 cell differentiation via the GRK2–A3AR–cAMP–PKA–CREB/ICER–RORγt axis. Inhibition of GRK2 by paroxetine or genetic GRK2 depletion restores A3AR membrane distribution and prevents Th17 differentiation.","method":"Receptor internalization assay, cAMP measurement, GRK2 inhibition (pharmacological and genetic), in vivo CIA rat model","journal":"Experimental cell research","confidence":"Medium","confidence_rationale":"Tier 2 — mechanistic pathway defined by GRK2 genetic depletion and pharmacological inhibition with biochemical readouts, replicated in vivo","pmids":["33434531"],"is_preprint":false},{"year":2025,"finding":"A3AR is expressed on the mitochondrial outer membrane of primary afferent sensory neurons. Ex vivo application of the selective A3AR agonist MRS5980 to saphenous nerve microfilaments from oxaliplatin-treated rats reversed deficits in mitochondrial ATP production, identifying a mitoprotective function of mitochondrial A3AR distinct from plasma membrane signaling.","method":"Subcellular fractionation/localization of A3AR, ex vivo ATP production assay on nerve microfilaments, in vivo IENF loss measurement, peripheral afferent spontaneous discharge recording","journal":"The Journal of neuroscience : the official journal of the Society for Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2 — direct localization to mitochondrial outer membrane tied to functional consequence (ATP rescue), with in vivo validation","pmids":["39653498"],"is_preprint":false},{"year":2024,"finding":"A3AR antagonist (FM101) induces β-arrestin2-mediated A3AR degradation, leading to mitochondrial dysfunction and necroptosis in monocyte-derived Kupffer cells (MoKCs), thereby reducing hepatic inflammation and fibrosis in MASLD. A3AR knockout mice showed analogous mitochondrial integrity disruption and KC necroptosis.","method":"A3AR KO mice, in vivo FM101 treatment, spatial transcriptomics, flow cytometry, immunofluorescence, mechanistic β-arrestin2 pathway analysis","journal":"Metabolism: clinical and experimental","confidence":"Medium","confidence_rationale":"Tier 2 — genetic KO corroborated by selective antagonist with defined β-arrestin2 mechanism, multiple orthogonal methods","pmids":["39732364"],"is_preprint":false},{"year":2013,"finding":"A3AR mediates pro-fibrotic signaling in renal proximal tubular cells: siRNA-mediated A3AR knockdown inhibits TGF-β1-induced fibronectin and collagen I upregulation. A3AR blockade reduces JNK and ERK phosphorylation and down-regulates lysyl oxidase, indicating that A3AR signals through MAPK pathways to promote extracellular matrix cross-linking and fibrosis.","method":"siRNA knockdown, selective antagonist LJ-1888, Western blot for JNK/ERK phosphorylation and ECM proteins, UUO mouse model","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 2 — siRNA KD confirms receptor specificity, MAPK pathway placement established biochemically with in vivo corroboration","pmids":["24001475"],"is_preprint":false},{"year":2024,"finding":"ADORA3 activation promotes goblet cell differentiation in colitis by enhancing HMGCS2-mediated ketogenesis. The produced β-hydroxybutyrate (BHB) increases HDAC1/2 activity, augmenting H3K9ac histone acetylation at the ATOH1 promoter to drive goblet cell fate. ADORA3 activation also controls competitive binding among β-arrestin2, SHP1, and PPARγ, resulting in non-ligand-dependent PPARγ activation that drives HMGCS2 transcription.","method":"Metabolomics, chromatin immunoprecipitation (H3K9ac), shHMGCS2 plasmid, A3AR antagonist MRS1191, in vivo DSS colitis model, in vitro mechanistic assays","journal":"International immunopharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — multi-step pathway established with metabolomics, ChIP, and genetic/pharmacological perturbations","pmids":["39098229"],"is_preprint":false},{"year":2024,"finding":"ADORA3 inhibition (MRS1523) promotes microglial phagocytosis of myelin debris via the cAMP/PKA/p-CREB pathway, ameliorating chronic ischemic white matter injury; the protective effect was reversed by PKA pathway inhibition, confirming the mechanistic pathway.","method":"BCAS mouse model, ADORA3 antagonist MRS1523, PKA inhibitor epistasis, qPCR, Western blot, immunofluorescence, flow cytometry","journal":"CNS neuroscience & therapeutics","confidence":"Medium","confidence_rationale":"Tier 2 — pharmacological epistasis with PKA inhibitor confirms pathway placement; multiple readouts in vivo","pmids":["38715283"],"is_preprint":false},{"year":2014,"finding":"Myeloperoxidase (MPO) enhances A3AR protein expression and vasoconstrictor responses in diabetic mice: STZ-treated wild-type mice showed augmented aortic vasoconstriction to Cl-IB-MECA and elevated A3AR protein, while MPO-deficient mice showed attenuated A3AR upregulation and reduced vasoconstriction under the same diabetic conditions.","method":"Isometric force measurements on aortic segments, Western blot for A3AR protein, MPO-knockout mice, dihydroethidium staining","journal":"Journal of cardiovascular pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 — MPO-KO genetic model with functional vascular assay establishes MPO as upstream regulator of A3AR expression and vascular signaling","pmids":["25000478"],"is_preprint":false},{"year":2010,"finding":"The ADORA3 promoter polymorphism haplotype ht1 (T-1050, C-564) is a high-transcript haplotype: luciferase reporter assay showed higher transcriptional activity, and EMSA identified a -564C allele-specific DNA-binding protein. This increased ADORA3 expression correlates with enhanced basophil histamine release, linking ADORA3 transcription level to mast cell/basophil mediator release.","method":"Luciferase reporter assay, EMSA, real-time PCR in PBMCs, histamine release assay","journal":"The British journal of dermatology","confidence":"Medium","confidence_rationale":"Tier 2 — functional promoter characterization by two orthogonal in vitro methods (luciferase + EMSA) linked to cellular phenotype","pmids":["20716228"],"is_preprint":false}],"current_model":"ADORA3 is a Gi protein-coupled receptor that, upon ligand binding at its orthosteric pocket (structurally defined by cryo-EM with key residues His3.37, Ser5.42, Ser6.52, and extracellular loop 3 governing selectivity), inhibits adenylate cyclase to reduce intracellular cAMP, and signals through downstream effectors including PKA, GSK-3β/β-catenin/Wnt, NF-κB, and MAPK (JNK/ERK) pathways; in sensory neurons it additionally inhibits N-type voltage-gated calcium channels (Cav2.2) and is expressed on the mitochondrial outer membrane where its activation preserves ATP production; receptor surface availability is regulated by GRK2-mediated internalization and β-arrestin2-dependent degradation, and in sperm a testis-specific isoform (A3Ri2/i3) couples through Gαi to modulate flagellar motility."},"narrative":{"teleology":[{"year":1995,"claim":"Establishing ADORA3 as a Gi-coupled receptor that inhibits adenylate cyclase provided the foundational signaling identity of the gene, resolving which G-protein family it engages.","evidence":"Chromosomal mapping of murine Adora3 by interspecific backcross with established Gi-coupling properties","pmids":["8595892"],"confidence":"Medium","gaps":["No direct biochemical measurement of Gi coupling in this study","Human receptor coupling not independently confirmed here"]},{"year":1997,"claim":"Cloning and structural characterization of the human ADORA3 gene revealed a single-intron architecture in the second intracellular loop and a TATA-less promoter, defining the transcriptional regulatory framework.","evidence":"Gene cloning, FISH mapping to 1p13.3, primer extension, and 5′ RACE in human tissues","pmids":["9293494"],"confidence":"High","gaps":["Promoter activity not functionally validated by reporter assay in this study","Cell-type-specific transcription factor usage unknown"]},{"year":2003,"claim":"Demonstrating that A3AR activation suppresses PKA, elevates GSK-3β, and destabilizes β-catenin/NF-κB in tumor cells established the receptor's anti-proliferative downstream signaling logic beyond simple cAMP reduction.","evidence":"Western blot signaling analysis in PC-3 prostate carcinoma cells treated with IB-MECA, validated in xenograft model","pmids":["12894581"],"confidence":"Medium","gaps":["No genetic knockout or rescue to rule out off-target pharmacology","Mechanism of PKAc downregulation not defined"]},{"year":2010,"claim":"Discovery of a testis-specific isoform (Adora3i2) that couples through Gαi to modulate sperm flagellar beat frequency revealed tissue-specific receptor diversification and a reproductive function for A3AR signaling.","evidence":"Heterologous expression in tsA-201 cells with cAMP assay; pertussis toxin blockade and Adora3i1-null sperm functional assays","pmids":["20732875"],"confidence":"High","gaps":["Male fertility phenotype of full Adora3 knockout not reported","Downstream effectors in sperm beyond Gαi not identified"]},{"year":2010,"claim":"Functional promoter polymorphism analysis linked a high-transcription haplotype to enhanced basophil histamine release, connecting ADORA3 expression level to allergic mediator output.","evidence":"Luciferase reporter assay and EMSA identifying allele-specific DNA-binding protein, correlated with PBMC expression and histamine release","pmids":["20716228"],"confidence":"Medium","gaps":["Identity of the -564C allele-specific transcription factor unknown","Functional impact on clinical allergy not established"]},{"year":2013,"claim":"siRNA-mediated knockdown established that A3AR is required for TGF-β1-induced MAPK (JNK/ERK) activation and extracellular matrix production in renal tubular cells, placing the receptor in pro-fibrotic signaling.","evidence":"siRNA knockdown and selective antagonist LJ-1888 in renal proximal tubular cells with UUO mouse model corroboration","pmids":["24001475"],"confidence":"Medium","gaps":["Direct receptor–MAPK coupling mechanism not resolved","Contribution relative to other adenosine receptors in fibrosis not quantified"]},{"year":2015,"claim":"Defining that A3AR agonists reverse neuropathic pain by restoring GABAergic signaling — via GAD65/GAT-1 phosphorylation and KCC2 activity — placed the receptor upstream of spinal inhibitory neurotransmission.","evidence":"In vivo CCI neuropathic pain models with intrathecal drug delivery; bicuculline reversal confirming GABAA dependence","pmids":["25878279"],"confidence":"Medium","gaps":["Cell type(s) mediating spinal A3AR analgesia not identified","Signaling intermediates between A3AR and KCC2/GAD65 phosphorylation unknown"]},{"year":2020,"claim":"Patch-clamp demonstration that A3AR agonists directly inhibit Cav2.2 N-type calcium channels in DRG neurons identified a specific ion channel effector for A3AR-mediated visceral analgesia.","evidence":"Whole-cell patch-clamp electrophysiology on isolated DRG neurons with selective A3AR and Cav2.2 antagonists","pmids":["32379223"],"confidence":"High","gaps":["G-protein subunit (Gβγ vs. Gαi) mediating Cav2.2 inhibition not resolved","Applicability beyond visceral pain models not tested"]},{"year":2021,"claim":"Showing that IL-6-driven GRK2-dependent A3AR internalization elevates cAMP and drives Th17 differentiation revealed receptor trafficking as a regulatory node in adaptive immunity.","evidence":"GRK2 pharmacological inhibition (paroxetine) and genetic depletion in T cells, with in vivo collagen-induced arthritis model","pmids":["33434531"],"confidence":"Medium","gaps":["Phosphorylation sites on A3AR targeted by GRK2 not mapped","Whether other kinases contribute to A3AR internalization in T cells not tested"]},{"year":2024,"claim":"Cryo-EM structures of agonist-bound A3AR–Gi complexes at 3.2–3.3 Å resolved the molecular basis of subtype selectivity, identifying extracellular loop 3 and a unique sub-pocket (His3.37, Ser5.42, Ser6.52) as determinants of activation.","evidence":"Cryo-EM structure determination of human A3AR with CF101/CF102 agonists plus heterotrimeric Gi, validated by functional mutagenesis","pmids":["38627384"],"confidence":"High","gaps":["Antagonist-bound structure not available","Structural basis for biased agonism (β-arrestin vs. G-protein) not determined"]},{"year":2024,"claim":"Identification of β-arrestin2-mediated A3AR degradation as a trigger for mitochondrial dysfunction and necroptosis in Kupffer cells defined a non-canonical receptor clearance pathway with therapeutic relevance in liver disease.","evidence":"A3AR KO mice and FM101 antagonist treatment with spatial transcriptomics, flow cytometry, and β-arrestin2 pathway analysis","pmids":["39732364"],"confidence":"Medium","gaps":["Ubiquitin ligase mediating β-arrestin2-dependent A3AR degradation not identified","Whether β-arrestin2 degradation pathway operates in non-hepatic macrophages unknown"]},{"year":2025,"claim":"Localization of A3AR to the mitochondrial outer membrane of sensory neurons, where its activation rescues ATP production, established a compartment-specific signaling function distinct from canonical plasma membrane GPCR activity.","evidence":"Subcellular fractionation and ex vivo ATP assay on saphenous nerve microfilaments from oxaliplatin-treated rats","pmids":["39653498"],"confidence":"Medium","gaps":["Mechanism of A3AR targeting to the mitochondrial outer membrane unknown","Whether mitochondrial A3AR couples to Gi at that location not demonstrated","Generalizability to non-neuronal cell types not established"]},{"year":null,"claim":"Key unresolved questions include the structural basis of biased agonism (G-protein vs. β-arrestin signaling), the mechanism of A3AR targeting to the mitochondrial outer membrane, and the identity of the G-protein subunit mediating Cav2.2 inhibition in sensory neurons.","evidence":"","pmids":[],"confidence":"High","gaps":["No antagonist-bound or β-arrestin-complexed structure available","Mitochondrial A3AR trafficking and coupling mechanism undefined","Gβγ vs. Gαi contribution to ion channel modulation not resolved"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[0,2,4,6]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7,6]},{"term_id":"GO:0005739","term_label":"mitochondrion","supporting_discovery_ids":[8]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[3,5,6,7,10,11,12]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[7,9]}],"complexes":[],"partners":["GNAI1","GRK2","ARRB2","CACNA1B"],"other_free_text":[]},"mechanistic_narrative":"ADORA3 encodes the A3 adenosine receptor, a Gi protein-coupled receptor that inhibits adenylate cyclase to reduce intracellular cAMP and engages multiple downstream signaling cascades — including PKA, GSK-3β/β-catenin/Wnt, NF-κB, and MAPK (JNK/ERK) — to regulate cell proliferation, immune cell differentiation, fibrosis, and pain processing [PMID:8595892, PMID:12894581, PMID:24001475]. Cryo-EM structures of the full-length human receptor in complex with Gi reveal an orthosteric agonist-binding pocket defined by His3.37, Ser5.42, and Ser6.52, with extracellular loop 3 governing subtype selectivity [PMID:38627384]. In sensory neurons, A3AR activation inhibits N-type voltage-gated calcium channels (Cav2.2) and, through a mitochondrial outer membrane-localized pool, preserves ATP production under chemotherapy-induced stress [PMID:32379223, PMID:39653498]. Receptor surface availability is controlled by GRK2-mediated internalization and β-arrestin2-dependent degradation, processes that determine Th17 differentiation in T cells and macrophage viability in the liver [PMID:33434531, PMID:39732364]."},"prefetch_data":{"uniprot":{"accession":"P0DMS8","full_name":"Adenosine receptor A3","aliases":[],"length_aa":318,"mass_kda":36.2,"function":"G protein-coupled receptor (GPCR) for adenosine that plays significant roles in various physiological processes including immune regulation, cardioprotection and neuroprotection (PubMed:38627384, PubMed:40825947, PubMed:9837869). Also acts as a receptor for adenosines containing N(6)-methylated adenine (m6A) post-transcriptional modification, which are derived from the degradation of RNAs (mRNAs, rRNAs and tRNAs): activated by N(6)-methyladenosine (m6A), N(6),N(6)-dimethyladenosine (m6,6A) and N(6)-isopentenyladenosine (i6A) (PubMed:33472058, PubMed:39511145). Preferentially couples to the inhibitory G protein (Gi), leading to the suppression of adenylate cyclase activity and a reduction in intracellular cyclic AMP levels (PubMed:33472058, PubMed:38627384). Upon adenosine binding, mediates cardioprotection in cardiomyocytes through anti-apoptotic effects primarily via the ERK1/2 pathway as well as the PI3K pathway (PubMed:9837869). In the central nervous system, participates in the modulation of synaptic plasticity, including long-term potentiation (LTP) and long-term depression (LTD) in the hippocampus (By similarity). In lung mast cells, receptor activation contributes to the type I allergic response by facilitating mast cell degranulation and histamine release (By similarity). Highly expressed in inflammatory cells such as neutrophils and mast cells, inhibits neutrophil degranulation and reduces superoxide production, thereby modulating inflammatory responses (PubMed:9164961) Receptor for adenosine. The activity of this receptor is mediated by G proteins which inhibits adenylyl cyclase (PubMed:8234299)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P0DMS8/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ADORA3","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":380,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ADORA3","total_profiled":1310},"omim":[{"mim_id":"621207","title":"TRANSMEMBRANE AND IMMUNOGLOBULIN DOMAINS-CONTAINING PROTEIN 3; TMIGD3","url":"https://www.omim.org/entry/621207"},{"mim_id":"600445","title":"ADENOSINE A3 RECEPTOR; ADORA3","url":"https://www.omim.org/entry/600445"},{"mim_id":"177650","title":"EXFOLIATION SYNDROME; XFS","url":"https://www.omim.org/entry/177650"},{"mim_id":"102776","title":"ADENOSINE A2A RECEPTOR; ADORA2A","url":"https://www.omim.org/entry/102776"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"brain","ntpm":19.8}],"url":"https://www.proteinatlas.org/search/ADORA3"},"hgnc":{"alias_symbol":["AD026","A3AR"],"prev_symbol":[]},"alphafold":{"accession":"P0DMS8","domains":[{"cath_id":"1.20.1070.10","chopping":"9-295","consensus_level":"medium","plddt":94.4707,"start":9,"end":295}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P0DMS8","model_url":"https://alphafold.ebi.ac.uk/files/AF-P0DMS8-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P0DMS8-F1-predicted_aligned_error_v6.png","plddt_mean":91.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ADORA3","jax_strain_url":"https://www.jax.org/strain/search?query=ADORA3"},"sequence":{"accession":"P0DMS8","fasta_url":"https://rest.uniprot.org/uniprotkb/P0DMS8.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P0DMS8/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P0DMS8"}},"corpus_meta":[{"pmid":"12894581","id":"PMC_12894581","title":"Targeting the A3 adenosine receptor for cancer therapy: inhibition of prostate carcinoma cell growth by A3AR agonist.","date":"2003","source":"Anticancer research","url":"https://pubmed.ncbi.nlm.nih.gov/12894581","citation_count":80,"is_preprint":false},{"pmid":"25878279","id":"PMC_25878279","title":"Engagement of the GABA to KCC2 signaling pathway contributes to the analgesic effects of A3AR agonists in neuropathic pain.","date":"2015","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/25878279","citation_count":67,"is_preprint":false},{"pmid":"26886128","id":"PMC_26886128","title":"The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis.","date":"2016","source":"Clinical rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/26886128","citation_count":50,"is_preprint":false},{"pmid":"24001475","id":"PMC_24001475","title":"The selective A3AR antagonist LJ-1888 ameliorates UUO-induced tubulointerstitial fibrosis.","date":"2013","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/24001475","citation_count":42,"is_preprint":false},{"pmid":"9293494","id":"PMC_9293494","title":"Cloning, characterisation and chromosomal assignment of the human adenosine A3 receptor (ADORA3) gene.","date":"1997","source":"Neuroscience research","url":"https://pubmed.ncbi.nlm.nih.gov/9293494","citation_count":31,"is_preprint":false},{"pmid":"29969887","id":"PMC_29969887","title":"Amitriptyline inhibits the MAPK/ERK and CREB pathways and proinflammatory cytokines through A3AR activation in rat neuropathic pain models.","date":"2018","source":"Korean journal of anesthesiology","url":"https://pubmed.ncbi.nlm.nih.gov/29969887","citation_count":30,"is_preprint":false},{"pmid":"38627384","id":"PMC_38627384","title":"Cryo-EM structures of adenosine receptor A3AR bound to selective agonists.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38627384","citation_count":30,"is_preprint":false},{"pmid":"20716228","id":"PMC_20716228","title":"Functional variability of the adenosine A3 receptor (ADORA3) gene polymorphism in aspirin-induced urticaria.","date":"2010","source":"The British journal of dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/20716228","citation_count":24,"is_preprint":false},{"pmid":"32379223","id":"PMC_32379223","title":"Acute visceral pain relief mediated by A3AR agonists in rats: involvement of N-type voltage-gated calcium channels.","date":"2020","source":"Pain","url":"https://pubmed.ncbi.nlm.nih.gov/32379223","citation_count":24,"is_preprint":false},{"pmid":"20732875","id":"PMC_20732875","title":"Testicular expression of Adora3i2 in Adora3 knockout mice reveals a role of mouse A3Ri2 and human A3Ri3 adenosine receptors in sperm.","date":"2010","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/20732875","citation_count":16,"is_preprint":false},{"pmid":"33434531","id":"PMC_33434531","title":"Down-regulation of A3AR signaling by IL-6-induced GRK2 activation contributes to Th17 cell differentiation.","date":"2021","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33434531","citation_count":14,"is_preprint":false},{"pmid":"29768061","id":"PMC_29768061","title":"Structural re-positioning, in silico molecular modelling, oxidative degradation, and biological screening of linagliptin as adenosine 3 receptor (ADORA3) modulators targeting hepatocellular carcinoma.","date":"2018","source":"Journal of enzyme inhibition and medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/29768061","citation_count":13,"is_preprint":false},{"pmid":"38715283","id":"PMC_38715283","title":"Inhibition of ADORA3 promotes microglial phagocytosis and alleviates chronic ischemic white matter injury.","date":"2024","source":"CNS neuroscience & therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/38715283","citation_count":11,"is_preprint":false},{"pmid":"8595892","id":"PMC_8595892","title":"Chromosomal mapping of the mouse A3 adenosine receptor gene, Adora3.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8595892","citation_count":10,"is_preprint":false},{"pmid":"39528760","id":"PMC_39528760","title":"METTL14 regulates inflammation in ulcerative colitis via the lncRNA DHRS4-AS1/miR-206/A3AR axis.","date":"2024","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/39528760","citation_count":9,"is_preprint":false},{"pmid":"36362112","id":"PMC_36362112","title":"Adenosine A3 Receptor (A3AR) Agonist for the Treatment of Bleomycin-Induced Lung Fibrosis in Mice.","date":"2022","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36362112","citation_count":9,"is_preprint":false},{"pmid":"25000478","id":"PMC_25000478","title":"Increased A3AR-dependent vasoconstriction in diabetic mice is promoted by myeloperoxidase.","date":"2014","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/25000478","citation_count":9,"is_preprint":false},{"pmid":"39732364","id":"PMC_39732364","title":"A3AR antagonism mitigates metabolic dysfunction-associated steatotic liver disease by exploiting monocyte-derived Kupffer cell necroptosis and inflammation resolution.","date":"2024","source":"Metabolism: clinical and experimental","url":"https://pubmed.ncbi.nlm.nih.gov/39732364","citation_count":7,"is_preprint":false},{"pmid":"39098229","id":"PMC_39098229","title":"ADORA3 activation promotes goblet cell differentiation via enhancing HMGCS2-mediated ketogenesis in ulcerative colitis.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39098229","citation_count":6,"is_preprint":false},{"pmid":"32969158","id":"PMC_32969158","title":"The impact of single nucleotide polymorphisms in ADORA2A and ADORA3 genes on the early response to methotrexate and presence of therapy side effects in children with juvenile idiopathic arthritis: Results of a preliminary study.","date":"2020","source":"International journal of rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/32969158","citation_count":6,"is_preprint":false},{"pmid":"39653498","id":"PMC_39653498","title":"Mitochondrial A3 Adenosine Receptor as a Mechanism for the Protective Effects of A3AR Agonists on Chemotherapy-Induced Neuropathic Pain.","date":"2025","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/39653498","citation_count":6,"is_preprint":false},{"pmid":"32448869","id":"PMC_32448869","title":"Analysis of association of ADORA2A and ADORA3 polymorphisms genotypes/haplotypes with efficacy and toxicity of methotrexate in patients with Rheumatoid arthritis.","date":"2020","source":"The pharmacogenomics journal","url":"https://pubmed.ncbi.nlm.nih.gov/32448869","citation_count":6,"is_preprint":false},{"pmid":"29955603","id":"PMC_29955603","title":"The Polymorphism in ADORA3 Decreases Transcriptional Activity and Influences the Chronic Heart Failure Risk in the Chinese.","date":"2018","source":"BioMed research international","url":"https://pubmed.ncbi.nlm.nih.gov/29955603","citation_count":4,"is_preprint":false},{"pmid":"38992885","id":"PMC_38992885","title":"The cumulative analgesic effect of repeated electroacupuncture is modulated by Adora3 in the SCDH of mice with neuropathic pain.","date":"2024","source":"Animal models and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/38992885","citation_count":4,"is_preprint":false},{"pmid":"38794149","id":"PMC_38794149","title":"The Impact of A3AR Antagonism on the Differential Expression of Chemoresistance-Related Genes in Glioblastoma Stem-like Cells.","date":"2024","source":"Pharmaceuticals (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/38794149","citation_count":2,"is_preprint":false},{"pmid":"40101576","id":"PMC_40101576","title":"Steric influence of 4'-position substituents and C2-Hexynyl group on A3AR antagonism in truncated 4'-Thioadenosine derivatives.","date":"2025","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40101576","citation_count":1,"is_preprint":false},{"pmid":"38341835","id":"PMC_38341835","title":"ADORA3: A Key Player in the Pathogenesis of Intracranial Aneurysms and a Potential Diagnostic Biomarker.","date":"2024","source":"Molecular diagnosis & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/38341835","citation_count":0,"is_preprint":false},{"pmid":"41231737","id":"PMC_41231737","title":"Inhibition of ADORA3 Accelerates Hematoma Resolution and Neurological Recovery after ICH.","date":"2025","source":"Cerebrovascular diseases (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/41231737","citation_count":0,"is_preprint":false},{"pmid":"41235759","id":"PMC_41235759","title":"Narirutin Reprograms Fatty Acid Metabolism and Inhibits Tumorigenesis via Downregulating ADORA3 Expression in Colorectal Cancer.","date":"2025","source":"Journal of gastroenterology and hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/41235759","citation_count":0,"is_preprint":false},{"pmid":"41404002","id":"PMC_41404002","title":"Design, Synthesis, and Biological Evaluation of C2-(N-Substituted Amino) Truncated 4'-Thioadenosine Derivatives as A2AAR and A3AR Dual Ligands.","date":"2025","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/41404002","citation_count":0,"is_preprint":false},{"pmid":"41404008","id":"PMC_41404008","title":"Discovery of a Novel Template, N3‑1'-Homologated 4'-Truncated Thiosugar-Substituted Xanthine as an A3AR Antagonist via Conversion of an A1AR Antagonist.","date":"2025","source":"ACS medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/41404008","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2024.11.13.623441","title":"Dysregulation of synaptic-related genes of neuroimmune networks within peripheral blood mononuclear cells in major depressive disorder","date":"2024-11-14","source":"bioRxiv","url":"https://doi.org/10.1101/2024.11.13.623441","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.09.23.24314219","title":"Digital phenotyping from wearables using AI characterizes psychiatric disorders and identifies genetic associations","date":"2024-09-24","source":"bioRxiv","url":"https://doi.org/10.1101/2024.09.23.24314219","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":18572,"output_tokens":4071,"usd":0.05839},"stage2":{"model":"claude-opus-4-6","input_tokens":7566,"output_tokens":5898,"usd":0.27792},"total_usd":0.33631,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2024,\n      \"finding\": \"Cryo-EM structures of full-length human A3AR bound to selective agonists CF101 and CF102 in complex with heterotrimeric Gi protein were resolved at 3.3–3.2 Å resolution. The agonists occupy the orthosteric pocket with conserved interactions via their adenine moieties, while their 3-iodobenzyl groups show distinct orientations. Extracellular loop 3 plays a critical role in ligand selectivity and receptor activation. Key residues His3.37, Ser5.42, and Ser6.52 in a unique sub-pocket significantly impact receptor activation.\",\n      \"method\": \"Cryo-EM structure determination with functional mutagenesis assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — atomic-resolution structure combined with functional mutagenesis validating key residues\",\n      \"pmids\": [\"38627384\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"The human ADORA3 gene encodes a Gi protein-coupled receptor; the coding region is interrupted by a single intron located in the second intracellular loop, a position conserved across adenosine receptor subtypes. The gene was mapped to chromosomal locus 1p13.3 by FISH. Multiple transcription start sites were identified; the promoter lacks CAAT and TATA boxes but contains putative binding sites for multiple transcription factors.\",\n      \"method\": \"Gene cloning, sequencing, fluorescence in situ hybridisation (FISH), primer extension, 5' RACE, Northern blot\",\n      \"journal\": \"Neuroscience research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct molecular characterization of gene structure and chromosomal localization with multiple orthogonal methods\",\n      \"pmids\": [\"9293494\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The mouse A3 adenosine receptor gene (Adora3) was mapped to chromosome 3 in tight linkage with DNA marker D3Bir15, consistent with its identity as a Gi protein-coupled receptor that inhibits adenylate cyclase upon ligand binding.\",\n      \"method\": \"Interspecific backcross panel Southern hybridization and haplotype analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct chromosomal mapping by genetic cross; functional characterization (Gi coupling, adenylate cyclase inhibition) stated as established property\",\n      \"pmids\": [\"8595892\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"A3AR activation by IB-MECA in PC-3 prostate carcinoma cells down-regulates PKAc expression, leading to increased GSK-3β protein levels, destabilization of β-catenin, and suppression of cyclin D1 and c-Myc. Concurrently, NF-κB/p65 expression is down-modulated, deregulating both Wnt and NF-κB signaling pathways to inhibit tumor cell growth.\",\n      \"method\": \"Western blot analysis of signaling proteins in vitro and in vivo (xenograft), thymidine incorporation assay\",\n      \"journal\": \"Anticancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological activation combined with protein-level readouts in vitro and in vivo, but no genetic rescue or reconstitution\",\n      \"pmids\": [\"12894581\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"In mouse sperm, Adora3i2 (a nested gene within Adora3) encodes a functional A3R isoform that couples through Gαi. When heterologously expressed in tsA-201 cells, Adora3i2 decreases forskolin-evoked cAMP accumulation. A3R-selective agonists (Cl-IB-MECA, IB-MECA) accelerate sperm flagellar beat frequency via pertussis-toxin-sensitive (Gαi/o) signaling; A1R, A2aR, and A2bR agonists are ineffective.\",\n      \"method\": \"Heterologous expression in tsA-201 cells with cAMP assay, pertussis toxin blockade, Adora3i1-null sperm functional assay, pharmacological profiling\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reconstitution of isoform in heterologous cells, Gi coupling confirmed biochemically, validated with knockout sperm and pertussis toxin\",\n      \"pmids\": [\"20732875\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A3AR agonists (IB-MECA and MRS5698) reverse CCI-induced neuropathic pain via a spinal mechanism that modulates GABAergic inhibitory neurotransmission. Specifically, A3AR activation reduces CCI-related GAD65 and GAT-1 serine dephosphorylation and enhances KCC2 serine phosphorylation and activity, restoring the chloride gradient. Spinal bicuculline (GABAA antagonist) disrupts A3AR-mediated analgesia.\",\n      \"method\": \"In vivo CCI neuropathic pain models (mouse and rat), intrathecal drug administration, phosphoprotein analysis, pharmacological antagonism\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — defined pathway placement by pharmacological epistasis (bicuculline reversal) in well-characterized animal models with biochemical readouts\",\n      \"pmids\": [\"25878279\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A3AR agonists (MRS5980 and Cl-IB-MECA) inhibit N-type voltage-gated Ca2+ channels (Cav2.2) in dorsal root ganglia neurons, as demonstrated by patch-clamp recordings; this effect is blocked by the selective A3AR antagonist MRS1523 and by the selective Cav2.2 blocker PD173212, establishing Cav2.2 inhibition as a mechanism of A3AR-mediated visceral analgesia.\",\n      \"method\": \"Patch-clamp electrophysiology on isolated DRG neurons, pharmacological antagonism in vivo and in vitro\",\n      \"journal\": \"Pain\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct electrophysiological measurement of ion channel inhibition by A3AR agonists, validated with selective antagonists\",\n      \"pmids\": [\"32379223\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"IL-6 stimulation of T cells promotes GRK2-dependent internalization of A3AR, increasing cAMP production and reducing PKA activity, which drives Th17 cell differentiation via the GRK2–A3AR–cAMP–PKA–CREB/ICER–RORγt axis. Inhibition of GRK2 by paroxetine or genetic GRK2 depletion restores A3AR membrane distribution and prevents Th17 differentiation.\",\n      \"method\": \"Receptor internalization assay, cAMP measurement, GRK2 inhibition (pharmacological and genetic), in vivo CIA rat model\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic pathway defined by GRK2 genetic depletion and pharmacological inhibition with biochemical readouts, replicated in vivo\",\n      \"pmids\": [\"33434531\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"A3AR is expressed on the mitochondrial outer membrane of primary afferent sensory neurons. Ex vivo application of the selective A3AR agonist MRS5980 to saphenous nerve microfilaments from oxaliplatin-treated rats reversed deficits in mitochondrial ATP production, identifying a mitoprotective function of mitochondrial A3AR distinct from plasma membrane signaling.\",\n      \"method\": \"Subcellular fractionation/localization of A3AR, ex vivo ATP production assay on nerve microfilaments, in vivo IENF loss measurement, peripheral afferent spontaneous discharge recording\",\n      \"journal\": \"The Journal of neuroscience : the official journal of the Society for Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization to mitochondrial outer membrane tied to functional consequence (ATP rescue), with in vivo validation\",\n      \"pmids\": [\"39653498\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"A3AR antagonist (FM101) induces β-arrestin2-mediated A3AR degradation, leading to mitochondrial dysfunction and necroptosis in monocyte-derived Kupffer cells (MoKCs), thereby reducing hepatic inflammation and fibrosis in MASLD. A3AR knockout mice showed analogous mitochondrial integrity disruption and KC necroptosis.\",\n      \"method\": \"A3AR KO mice, in vivo FM101 treatment, spatial transcriptomics, flow cytometry, immunofluorescence, mechanistic β-arrestin2 pathway analysis\",\n      \"journal\": \"Metabolism: clinical and experimental\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic KO corroborated by selective antagonist with defined β-arrestin2 mechanism, multiple orthogonal methods\",\n      \"pmids\": [\"39732364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"A3AR mediates pro-fibrotic signaling in renal proximal tubular cells: siRNA-mediated A3AR knockdown inhibits TGF-β1-induced fibronectin and collagen I upregulation. A3AR blockade reduces JNK and ERK phosphorylation and down-regulates lysyl oxidase, indicating that A3AR signals through MAPK pathways to promote extracellular matrix cross-linking and fibrosis.\",\n      \"method\": \"siRNA knockdown, selective antagonist LJ-1888, Western blot for JNK/ERK phosphorylation and ECM proteins, UUO mouse model\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — siRNA KD confirms receptor specificity, MAPK pathway placement established biochemically with in vivo corroboration\",\n      \"pmids\": [\"24001475\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ADORA3 activation promotes goblet cell differentiation in colitis by enhancing HMGCS2-mediated ketogenesis. The produced β-hydroxybutyrate (BHB) increases HDAC1/2 activity, augmenting H3K9ac histone acetylation at the ATOH1 promoter to drive goblet cell fate. ADORA3 activation also controls competitive binding among β-arrestin2, SHP1, and PPARγ, resulting in non-ligand-dependent PPARγ activation that drives HMGCS2 transcription.\",\n      \"method\": \"Metabolomics, chromatin immunoprecipitation (H3K9ac), shHMGCS2 plasmid, A3AR antagonist MRS1191, in vivo DSS colitis model, in vitro mechanistic assays\",\n      \"journal\": \"International immunopharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multi-step pathway established with metabolomics, ChIP, and genetic/pharmacological perturbations\",\n      \"pmids\": [\"39098229\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ADORA3 inhibition (MRS1523) promotes microglial phagocytosis of myelin debris via the cAMP/PKA/p-CREB pathway, ameliorating chronic ischemic white matter injury; the protective effect was reversed by PKA pathway inhibition, confirming the mechanistic pathway.\",\n      \"method\": \"BCAS mouse model, ADORA3 antagonist MRS1523, PKA inhibitor epistasis, qPCR, Western blot, immunofluorescence, flow cytometry\",\n      \"journal\": \"CNS neuroscience & therapeutics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — pharmacological epistasis with PKA inhibitor confirms pathway placement; multiple readouts in vivo\",\n      \"pmids\": [\"38715283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Myeloperoxidase (MPO) enhances A3AR protein expression and vasoconstrictor responses in diabetic mice: STZ-treated wild-type mice showed augmented aortic vasoconstriction to Cl-IB-MECA and elevated A3AR protein, while MPO-deficient mice showed attenuated A3AR upregulation and reduced vasoconstriction under the same diabetic conditions.\",\n      \"method\": \"Isometric force measurements on aortic segments, Western blot for A3AR protein, MPO-knockout mice, dihydroethidium staining\",\n      \"journal\": \"Journal of cardiovascular pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — MPO-KO genetic model with functional vascular assay establishes MPO as upstream regulator of A3AR expression and vascular signaling\",\n      \"pmids\": [\"25000478\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"The ADORA3 promoter polymorphism haplotype ht1 (T-1050, C-564) is a high-transcript haplotype: luciferase reporter assay showed higher transcriptional activity, and EMSA identified a -564C allele-specific DNA-binding protein. This increased ADORA3 expression correlates with enhanced basophil histamine release, linking ADORA3 transcription level to mast cell/basophil mediator release.\",\n      \"method\": \"Luciferase reporter assay, EMSA, real-time PCR in PBMCs, histamine release assay\",\n      \"journal\": \"The British journal of dermatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter characterization by two orthogonal in vitro methods (luciferase + EMSA) linked to cellular phenotype\",\n      \"pmids\": [\"20716228\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ADORA3 is a Gi protein-coupled receptor that, upon ligand binding at its orthosteric pocket (structurally defined by cryo-EM with key residues His3.37, Ser5.42, Ser6.52, and extracellular loop 3 governing selectivity), inhibits adenylate cyclase to reduce intracellular cAMP, and signals through downstream effectors including PKA, GSK-3β/β-catenin/Wnt, NF-κB, and MAPK (JNK/ERK) pathways; in sensory neurons it additionally inhibits N-type voltage-gated calcium channels (Cav2.2) and is expressed on the mitochondrial outer membrane where its activation preserves ATP production; receptor surface availability is regulated by GRK2-mediated internalization and β-arrestin2-dependent degradation, and in sperm a testis-specific isoform (A3Ri2/i3) couples through Gαi to modulate flagellar motility.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"ADORA3 encodes the A3 adenosine receptor, a Gi protein-coupled receptor that inhibits adenylate cyclase to reduce intracellular cAMP and engages multiple downstream signaling cascades — including PKA, GSK-3β/β-catenin/Wnt, NF-κB, and MAPK (JNK/ERK) — to regulate cell proliferation, immune cell differentiation, fibrosis, and pain processing [PMID:8595892, PMID:12894581, PMID:24001475]. Cryo-EM structures of the full-length human receptor in complex with Gi reveal an orthosteric agonist-binding pocket defined by His3.37, Ser5.42, and Ser6.52, with extracellular loop 3 governing subtype selectivity [PMID:38627384]. In sensory neurons, A3AR activation inhibits N-type voltage-gated calcium channels (Cav2.2) and, through a mitochondrial outer membrane-localized pool, preserves ATP production under chemotherapy-induced stress [PMID:32379223, PMID:39653498]. Receptor surface availability is controlled by GRK2-mediated internalization and β-arrestin2-dependent degradation, processes that determine Th17 differentiation in T cells and macrophage viability in the liver [PMID:33434531, PMID:39732364].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing ADORA3 as a Gi-coupled receptor that inhibits adenylate cyclase provided the foundational signaling identity of the gene, resolving which G-protein family it engages.\",\n      \"evidence\": \"Chromosomal mapping of murine Adora3 by interspecific backcross with established Gi-coupling properties\",\n      \"pmids\": [\"8595892\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct biochemical measurement of Gi coupling in this study\", \"Human receptor coupling not independently confirmed here\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Cloning and structural characterization of the human ADORA3 gene revealed a single-intron architecture in the second intracellular loop and a TATA-less promoter, defining the transcriptional regulatory framework.\",\n      \"evidence\": \"Gene cloning, FISH mapping to 1p13.3, primer extension, and 5′ RACE in human tissues\",\n      \"pmids\": [\"9293494\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter activity not functionally validated by reporter assay in this study\", \"Cell-type-specific transcription factor usage unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating that A3AR activation suppresses PKA, elevates GSK-3β, and destabilizes β-catenin/NF-κB in tumor cells established the receptor's anti-proliferative downstream signaling logic beyond simple cAMP reduction.\",\n      \"evidence\": \"Western blot signaling analysis in PC-3 prostate carcinoma cells treated with IB-MECA, validated in xenograft model\",\n      \"pmids\": [\"12894581\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic knockout or rescue to rule out off-target pharmacology\", \"Mechanism of PKAc downregulation not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery of a testis-specific isoform (Adora3i2) that couples through Gαi to modulate sperm flagellar beat frequency revealed tissue-specific receptor diversification and a reproductive function for A3AR signaling.\",\n      \"evidence\": \"Heterologous expression in tsA-201 cells with cAMP assay; pertussis toxin blockade and Adora3i1-null sperm functional assays\",\n      \"pmids\": [\"20732875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Male fertility phenotype of full Adora3 knockout not reported\", \"Downstream effectors in sperm beyond Gαi not identified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Functional promoter polymorphism analysis linked a high-transcription haplotype to enhanced basophil histamine release, connecting ADORA3 expression level to allergic mediator output.\",\n      \"evidence\": \"Luciferase reporter assay and EMSA identifying allele-specific DNA-binding protein, correlated with PBMC expression and histamine release\",\n      \"pmids\": [\"20716228\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the -564C allele-specific transcription factor unknown\", \"Functional impact on clinical allergy not established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"siRNA-mediated knockdown established that A3AR is required for TGF-β1-induced MAPK (JNK/ERK) activation and extracellular matrix production in renal tubular cells, placing the receptor in pro-fibrotic signaling.\",\n      \"evidence\": \"siRNA knockdown and selective antagonist LJ-1888 in renal proximal tubular cells with UUO mouse model corroboration\",\n      \"pmids\": [\"24001475\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor–MAPK coupling mechanism not resolved\", \"Contribution relative to other adenosine receptors in fibrosis not quantified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defining that A3AR agonists reverse neuropathic pain by restoring GABAergic signaling — via GAD65/GAT-1 phosphorylation and KCC2 activity — placed the receptor upstream of spinal inhibitory neurotransmission.\",\n      \"evidence\": \"In vivo CCI neuropathic pain models with intrathecal drug delivery; bicuculline reversal confirming GABAA dependence\",\n      \"pmids\": [\"25878279\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell type(s) mediating spinal A3AR analgesia not identified\", \"Signaling intermediates between A3AR and KCC2/GAD65 phosphorylation unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Patch-clamp demonstration that A3AR agonists directly inhibit Cav2.2 N-type calcium channels in DRG neurons identified a specific ion channel effector for A3AR-mediated visceral analgesia.\",\n      \"evidence\": \"Whole-cell patch-clamp electrophysiology on isolated DRG neurons with selective A3AR and Cav2.2 antagonists\",\n      \"pmids\": [\"32379223\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"G-protein subunit (Gβγ vs. Gαi) mediating Cav2.2 inhibition not resolved\", \"Applicability beyond visceral pain models not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that IL-6-driven GRK2-dependent A3AR internalization elevates cAMP and drives Th17 differentiation revealed receptor trafficking as a regulatory node in adaptive immunity.\",\n      \"evidence\": \"GRK2 pharmacological inhibition (paroxetine) and genetic depletion in T cells, with in vivo collagen-induced arthritis model\",\n      \"pmids\": [\"33434531\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphorylation sites on A3AR targeted by GRK2 not mapped\", \"Whether other kinases contribute to A3AR internalization in T cells not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Cryo-EM structures of agonist-bound A3AR–Gi complexes at 3.2–3.3 Å resolved the molecular basis of subtype selectivity, identifying extracellular loop 3 and a unique sub-pocket (His3.37, Ser5.42, Ser6.52) as determinants of activation.\",\n      \"evidence\": \"Cryo-EM structure determination of human A3AR with CF101/CF102 agonists plus heterotrimeric Gi, validated by functional mutagenesis\",\n      \"pmids\": [\"38627384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Antagonist-bound structure not available\", \"Structural basis for biased agonism (β-arrestin vs. G-protein) not determined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of β-arrestin2-mediated A3AR degradation as a trigger for mitochondrial dysfunction and necroptosis in Kupffer cells defined a non-canonical receptor clearance pathway with therapeutic relevance in liver disease.\",\n      \"evidence\": \"A3AR KO mice and FM101 antagonist treatment with spatial transcriptomics, flow cytometry, and β-arrestin2 pathway analysis\",\n      \"pmids\": [\"39732364\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitin ligase mediating β-arrestin2-dependent A3AR degradation not identified\", \"Whether β-arrestin2 degradation pathway operates in non-hepatic macrophages unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Localization of A3AR to the mitochondrial outer membrane of sensory neurons, where its activation rescues ATP production, established a compartment-specific signaling function distinct from canonical plasma membrane GPCR activity.\",\n      \"evidence\": \"Subcellular fractionation and ex vivo ATP assay on saphenous nerve microfilaments from oxaliplatin-treated rats\",\n      \"pmids\": [\"39653498\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of A3AR targeting to the mitochondrial outer membrane unknown\", \"Whether mitochondrial A3AR couples to Gi at that location not demonstrated\", \"Generalizability to non-neuronal cell types not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of biased agonism (G-protein vs. β-arrestin signaling), the mechanism of A3AR targeting to the mitochondrial outer membrane, and the identity of the G-protein subunit mediating Cav2.2 inhibition in sensory neurons.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No antagonist-bound or β-arrestin-complexed structure available\", \"Mitochondrial A3AR trafficking and coupling mechanism undefined\", \"Gβγ vs. Gαi contribution to ion channel modulation not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 4, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 6]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [8]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [3, 5, 6, 7, 10, 11, 12]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 6, 7, 10, 11, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 9]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GNAI1\",\n      \"GRK2\",\n      \"ARRB2\",\n      \"CACNA1B\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\nWait, I need to fix the pathway entries. I accidentally included a GO term that doesn't exist in the allowed list. Let me correct:\n\n```json\n{\n  \"mechanistic_narrative\": \"ADORA3 encodes the A3 adenosine receptor, a Gi protein-coupled receptor that inhibits adenylate cyclase to reduce intracellular cAMP and engages multiple downstream signaling cascades — including PKA, GSK-3β/β-catenin/Wnt, NF-κB, and MAPK (JNK/ERK) — to regulate cell proliferation, immune cell differentiation, fibrosis, and pain processing [PMID:8595892, PMID:12894581, PMID:24001475]. Cryo-EM structures of the full-length human receptor in complex with Gi reveal an orthosteric agonist-binding pocket defined by His3.37, Ser5.42, and Ser6.52, with extracellular loop 3 governing subtype selectivity [PMID:38627384]. In sensory neurons, A3AR activation inhibits N-type voltage-gated calcium channels (Cav2.2) and, through a mitochondrial outer membrane-localized pool, preserves ATP production under chemotherapy-induced stress [PMID:32379223, PMID:39653498]. Receptor surface availability is controlled by GRK2-mediated internalization and β-arrestin2-dependent degradation, processes that determine Th17 differentiation in T cells and macrophage viability in the liver [PMID:33434531, PMID:39732364].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Establishing ADORA3 as a Gi-coupled receptor that inhibits adenylate cyclase provided the foundational signaling identity of the gene, resolving which G-protein family it engages.\",\n      \"evidence\": \"Chromosomal mapping of murine Adora3 by interspecific backcross with established Gi-coupling properties\",\n      \"pmids\": [\"8595892\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No direct biochemical measurement of Gi coupling in this study\", \"Human receptor coupling not independently confirmed here\"]\n    },\n    {\n      \"year\": 1997,\n      \"claim\": \"Cloning and structural characterization of the human ADORA3 gene revealed a single-intron architecture in the second intracellular loop and a TATA-less promoter, defining the transcriptional regulatory framework.\",\n      \"evidence\": \"Gene cloning, FISH mapping to 1p13.3, primer extension, and 5′ RACE in human tissues\",\n      \"pmids\": [\"9293494\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Promoter activity not functionally validated by reporter assay in this study\", \"Cell-type-specific transcription factor usage unknown\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Demonstrating that A3AR activation suppresses PKA, elevates GSK-3β, and destabilizes β-catenin/NF-κB in tumor cells established the receptor's anti-proliferative downstream signaling logic beyond simple cAMP reduction.\",\n      \"evidence\": \"Western blot signaling analysis in PC-3 prostate carcinoma cells treated with IB-MECA, validated in xenograft model\",\n      \"pmids\": [\"12894581\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No genetic knockout or rescue to rule out off-target pharmacology\", \"Mechanism of PKAc downregulation not defined\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Discovery of a testis-specific isoform (Adora3i2) that couples through Gαi to modulate sperm flagellar beat frequency revealed tissue-specific receptor diversification and a reproductive function for A3AR signaling.\",\n      \"evidence\": \"Heterologous expression in tsA-201 cells with cAMP assay; pertussis toxin blockade and Adora3i1-null sperm functional assays\",\n      \"pmids\": [\"20732875\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Male fertility phenotype of full Adora3 knockout not reported\", \"Downstream effectors in sperm beyond Gαi not identified\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Functional promoter polymorphism analysis linked a high-transcription haplotype to enhanced basophil histamine release, connecting ADORA3 expression level to allergic mediator output.\",\n      \"evidence\": \"Luciferase reporter assay and EMSA identifying allele-specific DNA-binding protein, correlated with PBMC expression and histamine release\",\n      \"pmids\": [\"20716228\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Identity of the -564C allele-specific transcription factor unknown\", \"Functional impact on clinical allergy not established\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"siRNA-mediated knockdown established that A3AR is required for TGF-β1-induced MAPK (JNK/ERK) activation and extracellular matrix production in renal tubular cells, placing the receptor in pro-fibrotic signaling.\",\n      \"evidence\": \"siRNA knockdown and selective antagonist LJ-1888 in renal proximal tubular cells with UUO mouse model corroboration\",\n      \"pmids\": [\"24001475\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor–MAPK coupling mechanism not resolved\", \"Contribution relative to other adenosine receptors in fibrosis not quantified\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Defining that A3AR agonists reverse neuropathic pain by restoring GABAergic signaling — via GAD65/GAT-1 phosphorylation and KCC2 activity — placed the receptor upstream of spinal inhibitory neurotransmission.\",\n      \"evidence\": \"In vivo CCI neuropathic pain models with intrathecal drug delivery; bicuculline reversal confirming GABAA dependence\",\n      \"pmids\": [\"25878279\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Cell type(s) mediating spinal A3AR analgesia not identified\", \"Signaling intermediates between A3AR and KCC2/GAD65 phosphorylation unknown\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Patch-clamp demonstration that A3AR agonists directly inhibit Cav2.2 N-type calcium channels in DRG neurons identified a specific ion channel effector for A3AR-mediated visceral analgesia.\",\n      \"evidence\": \"Whole-cell patch-clamp electrophysiology on isolated DRG neurons with selective A3AR and Cav2.2 antagonists\",\n      \"pmids\": [\"32379223\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"G-protein subunit (Gβγ vs. Gαi) mediating Cav2.2 inhibition not resolved\", \"Applicability beyond visceral pain models not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Showing that IL-6-driven GRK2-dependent A3AR internalization elevates cAMP and drives Th17 differentiation revealed receptor trafficking as a regulatory node in adaptive immunity.\",\n      \"evidence\": \"GRK2 pharmacological inhibition (paroxetine) and genetic depletion in T cells, with in vivo collagen-induced arthritis model\",\n      \"pmids\": [\"33434531\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Phosphorylation sites on A3AR targeted by GRK2 not mapped\", \"Whether other kinases contribute to A3AR internalization in T cells not tested\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Cryo-EM structures of agonist-bound A3AR–Gi complexes at 3.2–3.3 Å resolved the molecular basis of subtype selectivity, identifying extracellular loop 3 and a unique sub-pocket (His3.37, Ser5.42, Ser6.52) as determinants of activation.\",\n      \"evidence\": \"Cryo-EM structure determination of human A3AR with CF101/CF102 agonists plus heterotrimeric Gi, validated by functional mutagenesis\",\n      \"pmids\": [\"38627384\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Antagonist-bound structure not available\", \"Structural basis for biased agonism (β-arrestin vs. G-protein) not determined\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Identification of β-arrestin2-mediated A3AR degradation as a trigger for mitochondrial dysfunction and necroptosis in Kupffer cells defined a non-canonical receptor clearance pathway with therapeutic relevance in liver disease.\",\n      \"evidence\": \"A3AR KO mice and FM101 antagonist treatment with spatial transcriptomics, flow cytometry, and β-arrestin2 pathway analysis\",\n      \"pmids\": [\"39732364\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ubiquitin ligase mediating β-arrestin2-dependent A3AR degradation not identified\", \"Whether β-arrestin2 degradation pathway operates in non-hepatic macrophages unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Localization of A3AR to the mitochondrial outer membrane of sensory neurons, where its activation rescues ATP production, established a compartment-specific signaling function distinct from canonical plasma membrane GPCR activity.\",\n      \"evidence\": \"Subcellular fractionation and ex vivo ATP assay on saphenous nerve microfilaments from oxaliplatin-treated rats\",\n      \"pmids\": [\"39653498\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of A3AR targeting to the mitochondrial outer membrane unknown\", \"Whether mitochondrial A3AR couples to Gi at that location not demonstrated\", \"Generalizability to non-neuronal cell types not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis of biased agonism (G-protein vs. β-arrestin signaling), the mechanism of A3AR targeting to the mitochondrial outer membrane, and the identity of the G-protein subunit mediating Cav2.2 inhibition in sensory neurons.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No antagonist-bound or β-arrestin-complexed structure available\", \"Mitochondrial A3AR trafficking and coupling mechanism undefined\", \"Gβγ vs. Gαi contribution to ion channel modulation not resolved\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [0, 2, 4, 6]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [6, 7]},\n      {\"term_id\": \"GO:0005739\", \"supporting_discovery_ids\": [8, 9]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [3, 5, 6, 7, 10, 11, 12]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [7, 9]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [5, 6]},\n      {\"term_id\": \"R-HSA-1474165\", \"supporting_discovery_ids\": [4]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\n      \"GNAI1\",\n      \"GRK2\",\n      \"ARRB2\",\n      \"CACNA1B\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}